VIDEO: Recent FDA approvals impact DME practice

Editor's note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

Well, 2023 was kind of a remarkable year for diabetic macular edema. You know, we initially had approval of faricimab, which is a molecule for the first time that’s not just targeting anti-VEGF but also angiopoietin-2. So, I think there’s another entire pathway of disease pathophysiology that’s getting targeted. And then recently towards the end of 2023, we have approval of 8 mg aflibercept, which is quadruple the dose of what we’re currently using with 2 mg aflibercept. So, I think it’s certainly a really, really great time in diabetic macular edema because just in this year alone, we’ve had two treatments that have resulted in not only improved anatomic outcomes for our patients but also a longer duration between injections.